Evidence Explorer · MS-N275 · Supportive physical care · Appraised November 8, 2026
In a 108-participant three-arm trial, exercise added to compression was associated with less grade 2 neuropathy after four albumin-bound paclitaxel cycles than standard care or compression alone. The combined design cannot isolate the exercise contribution, and several secondary biomarker and weight findings do not establish nerve recovery.
Evidence at a glance
- Population: 108 women receiving albumin-bound paclitaxel 250 mg/m² with peripheral neuropathy.
- Intervention: EXCAP exercise plus compression.
- Comparators: compression alone and general treatment.
- Key result: grade 2 CIPN was 0% with the combined program, 25% with compression and 50% with general treatment after four cycles (P<.001).
- Evidence label: positive single-center combination-program evidence; replication and full safety reporting needed.
What was studied
Participants were randomized to three groups. The report also found higher 25-hydroxyvitamin D and lower BMI with the combined program. Those are secondary outcomes and should not be interpreted as mechanisms or proof of neurologic recovery.
The accessible report did not clarify whether all 108 were analyzed, how neuropathy was adjudicated, whether assessors were blinded, or whether exercise and compression adherence differed.
What this evidence cannot establish
Because exercise and compression were combined, the trial cannot say which component drove the result. It does not establish benefit for chronic CIPN, other chemotherapy regimens, falls, objective nerve conduction or cancer outcomes.
Safety and practical context
Exercise should be adapted for falls, weakness, bone metastases, cytopenias, cardiac disease and acute treatment toxicity. Compression requires circulation, skin and fit checks. New motor weakness, asymmetry or bowel/bladder symptoms require prompt assessment.
Questions for the care team
- Which part of the combined program is feasible and measurable for me?
- How will fall risk, skin integrity and circulation be checked?
- Will we track patient-reported symptoms, function and chemotherapy dose changes—not just biomarkers?
Sources and identifiers
- Three-arm randomized trial — PMID 41443031
Funding and conflicts: The accessible PubMed report did not provide verified funding, conflict or detailed adverse-event information.
Source access and dates: Original PubMed records and available full texts were checked November 8, 2026. Last literature search November 8, 2026.
Educational evidence summary, not individualized medical advice. Supportive-care outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
